FASN and cancer: Targeting the lipid and cholesterol dependence of cancer cell inhibitor agents directed against lipogenic enzymes (FASN, ACLY and ACC) has been the subject of numerous studies; and their efficacy as anticancer therapies has been proven in various preclinical models of carcinogenesis [70–72].